Search research articles
Contact Us
Filters
Showing results (91-100 of 95) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 95 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
H C Pitot, R M Goldberg, J M Reid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)
H H Yoon, N R Foster, J P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
M J O'Connell, J A Laurie, M Kahn, et al.
Investigational New Drugs
|
June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
B B Y Ma, B C Goh, W T Lim, et al.
Leukemia
|
November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
A Dispenzieri, G A Wiseman, M Q Lacy, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 95) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 95 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
H C Pitot, R M Goldberg, J M Reid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)
H H Yoon, N R Foster, J P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
M J O'Connell, J A Laurie, M Kahn, et al.
Investigational New Drugs
|
June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
B B Y Ma, B C Goh, W T Lim, et al.
Leukemia
|
November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
A Dispenzieri, G A Wiseman, M Q Lacy, et al.
Page
of 10